Quantum BioPharma Ltd.

QNTM

CA74764Y2050

Biotechnology & Medical Research

Delayed Canadian Securities Exchange Other stock markets 09:34:23 2024-09-16 am EDT			5-day change	1st Jan Change
5.230 ^CAD	-3.33%		+0.38%	-93.29%

Sep. 13	Quantum BioPharma Ltd. announced that it has received CAD 0.000036 million in funding from Fortius Research and Trading Corporation	CI
Sep. 13	Quantum BioPharma Ltd. announced that it has received CAD 0.000036 million in funding from Fortius Research and Trading Corporation, Xorax Family Trust	CI

FSD Pharma Inc. will Change its Ticker to QNTM from HUGE

August 15, 2024 at 12:00 am EDT

Effective August 15, 2024, FSD Pharma Inc. will change its Canadian National Stock Exchange stock ticker symbol to QNTM from HUGE.

Latest news about Quantum BioPharma Ltd.

Quantum BioPharma Ltd. announced that it has received CAD 0.000036 million in funding from Fortius Research and Trading Corporation	Sep. 12	CI
Quantum BioPharma Ltd. announced that it has received CAD 0.000036 million in funding from Fortius Research and Trading Corporation, Xorax Family Trust	Sep. 12	CI
September Kicks Off With US Futures Moving Lower Ahead of Manufacturing Data	Sep. 03	MT
Quantum Biopharma Announces Celly Nutrition Launches Unbuzzd(Tm) Grab-And-Go Stick Packs on Amazon.Com So You Can "Own Now and What?S Next"	Aug. 30	CI
Quantum BioPharma Ltd. Announces Executive Appointments	Aug. 23	CI
Quantum BioPharma Ltd. Announces the Appointment of Donal Carroll as Chief Financial Officer, Effective August 30, 2024	Aug. 23	CI
FSD Pharma Inc. will Change its Name to Quantum BioPharma Ltd	Aug. 15	CI
FSD Pharma Inc. will Change its Ticker to QNTM from HUGE	Aug. 15	CI
Quantum BioPharma Ltd. announced that it has received CAD 0.000072 million in funding from Fortius Research and Trading Corp and other investors	Aug. 14	CI
Tranche Update on Quantum BioPharma Ltd.'s Equity Buyback Plan announced on January 13, 2023.	Aug. 14	CI
Quantum BioPharma Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 14	CI
FSD Pharma $2 Million Arbitration Award Upheld by Federal Court Against Former CEO	Jun. 28	MT
Sector Update: Health Care Stocks Decline in Late Afternoon Trading	Jun. 28	MT
FSD Pharma $2 Million Arbitration Award Upheld by Federal Court Against Former CEO	Jun. 28	MT
FSD Pharma $2 Million Arbitration Award Upheld by Federal Court Against Former CEO	Jun. 28	MT
FSD Pharma Inc. announced that it has received CAD 0.195 million in funding	Jun. 27	CI
FSD Pharma Inc. Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia	Jun. 27	CI
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication	Jun. 04	CI
FSD Pharma Slightly Lower In US Premarket As Submits Clinical Trial Protocol to Study Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication	May. 28	MT
FSD Pharma Inc. Submits A Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication	May. 28	CI
Tranche Update on Quantum BioPharma Ltd.'s Equity Buyback Plan announced on January 13, 2023.	May. 14	CI
Quantum BioPharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
FSD Pharma Inc. Submits A Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia	May. 07	CI
FSD Pharma Inc. Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of Unbuzzd? in an Induced State of Alcohol Intoxication	Apr. 30	CI
FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement	Apr. 25	MT

Quantum BioPharma Ltd, formerly FSD Pharma Inc., is a biotechnology company. It operates in two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of its two primary drug candidates, consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. Its Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.

Employees

Sector

Biotechnology & Medical Research

Calendar

2024-11-12 - Q3 2024 Earnings Release (Projected)

More about the company

Quantum BioPharma Ltd.

Equities

QNTM

CA74764Y2050

Biotechnology & Medical Research

FSD Pharma Inc. will Change its Ticker to QNTM from HUGE

Latest news about Quantum BioPharma Ltd.

Chart Quantum BioPharma Ltd.

Company Profile